ABCD of the phosphodiesterase family: Interaction and differential activity in COPD

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 543-561

  Halpin, David M G ^a  

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

Anti inflammatory; Bronchodilator; COPD; Phosphodiesterase; Pulmonary vasodilator

Indexed keywords

AMANTADINE; AROFYLLINE; AWD 12281; BAY 19 8004; BAY 198004; BETA ARRESTIN; CILOMILAST; CILOSTAMIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; ENOXIMONE; FELODIPINE; G PROTEIN COUPLED RECEPTOR; L 826141; LIXAZINONE; NICARDIPINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VII; PLACEBO; RETINA S ANTIGEN; ROFLUMILAST; ROLIPRAM; SELEGILINE; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINPOCETINE;

ABDOMINAL PAIN; AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLITIS; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; GASTROINTESTINAL SYMPTOM; HUMAN; METAL BINDING; NAUSEA; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH ACID SECRETION; UNSPECIFIED SIDE EFFECT; VOMITING;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; CYCLIC AMP; HUMANS; ISOENZYMES; LUNG; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS; SECOND MESSENGER SYSTEMS;

EID: 60249089353     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (228)

1. Agostini C, Trentin L, Adami F. 2003. Chronic obstructive pulmonary disease (COPD): new insights on the events leading to pulmonary inflammation. Sarcoidosis Vasc Diffuse Lung Dis, 20:3-7.
2. Agusti AG, Noguera A, Sauleda J, et al. 2003. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J, 21, 347-60.
3. Alexander RP, Warrellow GJ, Eaton MA, et al. 2002. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors. Bioorg Med Chem Lett, 12:1451-6.
4. Aoki M, Kobayashi M, Ishikawa J, et al. 2000. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido [2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J Pharmacol Exp Ther, 295:255-60.
5. Aravind L, Koonin EV. 1998. The HD domain defines a new superfamily of metal-dependent phosphohydrolases. Trends Biochem Sci, 23:469-72.
6. Aravind L, Ponting CP. 1997. The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci, 22:458-9.
7. Asirvatham AL, Galligan SG, Schillace RV, et al. 2004. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol, 173:4806-14.
8. Baillie GS, Sood A, Mcphee I, et al. 2003. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A, 100:940-5.
9. Barber R, Baillie GS, Bergmann R, et al. 2004. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol, 287:L332-43.
10. Barnes AP, Livera G, Huang P, et al. 2005. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem, 280:7997-8003.
11. Barnette MS. 1999. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res, 53:193-229.
12. Barnette MS, Christensen SB, Essayan DM, et al. 1998. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol Exp Ther, 284:420-6.
13. Baumer W, Hoppmann J, Rundfeldt C, et al. 2007. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets, 6:17-26.
14. Beard MB, Huston E, Campbell L, et al. 2002. In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting. Cell Signal, 14:453-65.
15. Beavo JA, Brunton LL. 2002. Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol, 3:710-8.
16. Beavo JA, Conti M, Heaslip RJ. 1994. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol, 46:399-405.
17. Beleta J, Bou J, Miralpeix M, et al. 1996. LAS 31025, a new compound with selective phosphodiesterase IV inhibitory activity. Third International Conference on Cyclic Nucleotide Phosphodiesterases: From Genes to Therapies. Glasgow.
18. Bender AT, Beavo JA. 2006, PDE1B2 regulates cGMP and a subset of the phenotypic characteristics acquired upon macrophage differentiation from a monocyte. Proc Natl Acad Sci U S A, 103:460-5.
19. Bender AT, Ostenson CL, Wang EH, et al. 2005. Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation. Proc Natl Acad Sci U S A, 102:497-502.
20. Billah MM, Cooper N, Minnicozzi M, et al. 2002. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2- (trifluoromethyl)-5-quino line carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther, 302:127-37.
21. Bingham J, Sudarsanam S, Srinivasan S. 2006. Profiling human phosphodiesterase genes and splice isoforms. Biochem Biophys Res Commun, 350:25-32.
22. Bloom TJ, Beavo JA. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci U S A, 93:14188-92.
23. Blount MA, Beasley A, Zoraghi R, et al. 2004. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol, 66:144-52.
24. Bolger G, Michaeli T, Martins T, et al. 1993. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol, 13:6558-71.
25. Bolger GB. 1994. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal, 6:851-9.
26. Bolger GB, Peden AH, Steele MR, et al. 2003. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem, 278:33351-63.
27. Boot JD, De Haas SL, Van Gerven JM, et al. 2008. MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. In press.
28. Borgeat P, Chavancy G, Dupont A, et al. 1972. Stimulation of adenosine 3′:5′-cyclic monophosphate accumulation in anterior pituitary gland in vitro by synthetic luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A, 69:2677-81.
29. Bos JL. 2003. Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol, 4:733-8.
30. Bourne HR, Lichtenstein LM, Melmon KL, et al. 1974. Modulation of inflammation and immunity by cyclic AMP. Science, 184:19-28.
31. Breer H. 1993. Second messenger signalling in olfaction. Ciba Found Symp, 179:97-109; discussion 109-14, 147-9.
32. Buckley G, Cooper N, Dyke HJ, et al. 2000. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma. Bioorg Med Chem Lett, 10:2137-40.
33. Bundschuh DS, Eltze M, Barsig J, et al. 2001. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther, 297:280-90.
34. Burnouf C, Auclair E, Avenel N, et al. 2000. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors. J Med Chem, 43:4850-67.
35. Calverley PM, Sanchez-Toril F, McIvor A, et al. 2007. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 176:154-61.
36. Charan NB. 2001. Does sildenafil also improve breathing? Chest, 120:305-6.
37. Chen JC, Chen JQ, Xie QM, et al. 2004. Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram. Acta Pharmacol Sin, 25:1171-5.
38. Chihiro M, Nagamoto H, Takemura I, et al. 1995. Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. J Med Chem, 38:353-8.
39. Christensen SB, Guider A, Forster CJ, et al. 1998. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J Med Chem, 41:821-35.
40. Claveau D, Chen SL, O'Keefe S, et al. 2004. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro- 2-hydroxy propan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther, 310:752-60.
41. Compton CH, Gubb J, Nieman R, et al. 2001. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet, 358:265-70.
42. Conti M, Beavo J. 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem, 76:481-511.
43. Conti M, Jin SL. 1999. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol, 63:1-38.
44. Corbin JD, Blount MA, Weeks JL 2nd, et al. 2003. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol, 63:1364-72.
45. Corbin JD, Francis SH. 1999. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem, 274:13729-32.
46. Corbin JD, Turko IV, Beasley A, et al. 2000. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem, 267:2760-7.
47. De Boer J, Philpott AJ, Van Amsterdam RG, et al. 1992. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol, 106:1028-34.
48. Degerman E, Belfrage P, Manganiello VC. 1997. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem, 272:6823-6.
49. Dent G, Giembycz MA, Evans PM, et al. 1994. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther, 271:1167-74.
50. Dent G, White SR, Tenor H, et al. 1998. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther, 11:47-56.
51. Dodge-Kafka KL, Soughayer J, Pare GC, et al. 2005. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature, 437:574-8.
52. Dodge KL, Khouangsathiene S, Kapiloff MS, et al. 2001. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J, 20:1921-30.
53. Dolci S, Belmonte A, Santone R, et al. 2006. Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochem Biophys Res Commun, 341:837-46.
54. Duplantier AJ, Bachert EL, Cheng JB, et al. 2007. SAR of a series of 5,6-dihydro-(9H)-pyrazolo [3,4-c]-1,2,4-triazolo[4,3- alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J Med Chem, 50:344-9.
55. Enefer S. 2005. Inflammation 2005-Seventh World Congress. Highlights I. IDrugs, 8:788-90.
56. Engels P, Fichtel K, Lubbert H. 1994. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett, 350:291-5.
57. Engels P, Sullivan M, Muller T, et al. 1995. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett, 358:305-10.
58. Evgenov OV, Busch CJ, Evgenov NV, et al. 2006. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 290:L723-L9.
59. Fidock M, Miller M, Lanfear J. 2002. Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants. Cell Signal, 14:53-60.
60. Francis SH, Lincoln TM, Corbin JD. 1980. Characterization of a novel cGMP binding protein from rat lung. J Biol Chem, 255:620-6.
61. Francis SH, Turko IV, Corbin JD. 2001. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol, 65:1-52.
62. Friedman DL, Johnson RA, Zeilig CE. 1976. The role of cyclic nucleotides in the cell cycle. Adv Cyclic Nucleotide Res, 7:69-114.
63. Fujimura M, Kamio Y, Saito M, et al. 1995. Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. Am J Respir Crit Care Med, 151:222-5.
64. Fukao M, Mason HS, Britton FC, et al. 1999. Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072. J Biol Chem, 274:10927-35.
65. Furuie H, Nakagawa S, Kawashima M, et al. 2003. Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects. Eur Respir J, 22(Suppl 45):395s.
66. Gale DD, Landells LJ, Spina D, et al. 2002. Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol, 54:478-84.
67. Gamble F, Grootendorst DC, Brightling CE, et al. 2003. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 168:976-82.
68. Gardner C, Robas N, Cawkill D, et al. 2000. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun, 272:186-92.
69. Ghofrani HA, Voswinckel R, Reichenberger F, et al. 2004. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol, 44:1488-96.
70. Giembycz MA. 2005. Phosphodiesterase-4. Selective and dual specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2:326-333.
71. Giembycz MA, Corrigan CJ, Seybold J, et al. 1996. Identification of cyclic AMP phosphodiesterases 3,4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol, 118:1945-58.
72. Giovannoni MP, Cesari N, Graziano A, et al. 2007. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors. J Enzyme Inhib Med Chem, 22:309-18.
73. Glavas NA, Ostenson C, Schaefer JB, et al. 2001. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci U S A, 98:6319-24.
74. Global Initiative for Chronic Obstructive Pulmonary Disease. 2006. Global strategy for the diagnosis, management and prevention of chronicobstructive pulmonary disease, Executive Summary. URL: www.goldcopd.com.
75. Grashoff WF, Sont JK, Sterk PJ, et al. 1997. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol, 151:1785-90.
76. Griswold DE, Webb EF, Badger AM, et al. 1998. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther, 287:705-11.
77. Grootendorst DC, Gauw SA, Benschop N, et al. 2003. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther, 16:341-7.
78. Gutke HJ, Guse JH, Khobzaoui M, et al. 2005. AWD-12-281 (inhaled) (elbion/GlaxoSmithKline). Curr Opin Investig Drugs, 6:1149-58.
79. Habener JF. 2001. The cyclic AMP second messenger signaling pathway. In: Degroo, LJ, Jameson JL (eds). Endocrinology. Philadelphia:WB Saunders.
80. Halpin DMG. 2007. Systemic Effects of COPD. Expert Rev Resp Med, 1:75-84.
81. Hambleton R, Krall J, Tikishvili E, et al. 2005. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem, 280:39168-74.
82. Han P, Fletcher CF, Copeland NG, et al. 1998. Assignment of the mouse Pde7A gene to the proximal region of chromosome 3 and of the human PDE7A gene to chromosome 8q13. Genomics, 48:275-6.
83. Han P, Sonati P, Rubin C, et al. 2006. PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C. J Biol Chem, 281:15050-7.
84. Han P, Zhu X, Michaeli T. 1997/Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem, 272:16152-7.
85. Hatzelmann A, Schudt C. 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther, 297:267-79.
86. Heaslip RJ, Lombardo LJ, Golankiewicz JM, et al. 1994. Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J Pharmacol Exp Ther, 268:888-96.
87. Hetman JM, Soderling SH, Glavas NA, et al. 2000. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci U S A, 97:472-6.
88. Hogg JC, Chu F, Utokaparch S, et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med, 350:2645-53.
89. Horowski R, Sastre-Y-Hernandez M. 1985. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res, 38:23-9.
90. Horton YM, Sullivan M, Houslay MD. 1995. Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected]. Biochem J, 308:683-91.
91. Houslay MD, Schafer P, Zhang KY. 2005. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today, 10:1503-19.
92. Huang Z, Liu S, Zhang L, et al. 2006. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sci, 78:2663-8.
93. Jeffery PK. 2001a. Lymphocytes, chronic bronchitis and chronic obstructive pulmonary disease. Novartis Found Symp, 234:149-61; discussion 161-8.
94. Jeffery PK. 2001b. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med, 164:S28-38.
95. Jeon YH, Heo YS, Kim CM, et al. 2005. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci, 62:1198-220.
96. Jiang X, Li J, Paskind M, Epstein PM. 1996. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci U S A, 93:11236-41.
97. Jin SL, Conti M. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A, 99:7628-33.
98. Kakiuchi S, Yamazaki R. 1970. Calcium dependent phosphodiesterase activity and its activating factor (PAF) from brain studies on cyclic 3′,5′-nucleotide phosphodiesterase (3). Biochem Biophys Res Commun, 41:1104-10.
99. Kakkar R, Raju RV, Rajput AH, et al. 1996. Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Life Sci, 59:337-41.
100. Kakkar R, Raju RV, Rajput AH, et al. 1997. Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res, 749:290-4.
101. Kakkar R, Raju RV, Sharma RK. 1999. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci, 55:1164-86.
102. Kammer GM. 1988. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today, 9:222-9.
103. Kanda N, Watanabe S. 2001. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem Pharmacol, 62:495-507.
104. Kasuya J, Liang SJ, Goko H, et al. 2000. Cardiac type cGMP-inhibited phosphodiesterase (PDE3A) gene structure: similarity and difference to adipocyte type PDE3B gene. Biochem Biophys Res Commun, 268:827-34.
105. Kirstein M, Rivet-Bastide M, Hatem S, et al. 1995. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest, 95:794-802.
106. Kitamura T, Kitamura Y, Kuroda S, et al. 1999. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol, 19:6286-96.
107. Kotera J, Fujishige K, Akatsuka H, et al. 1998. Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem, 273:26982-90.
108. Kovala T, Sanwal BD, Ball EH. 1997. Recombinant expression of a type IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants. Biochemistry, 36:2968-76.
109. Koyama H, Bornfeldt KE, Fukumoto S, et al. 2001. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol, 186:1-10.
110. Kucharekova M, Hornix M, Ashikaga T, et al. 2003. The effect of the PDE-4 inhibitor (cipamfylline) in two human models of irritant contact dermatitis. Arch Dermatol Res, 295:29-32.
111. Ledbetter JA, Parsons M, Martin PJ, et al. 1986. Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol, 137:3299-305.
112. Lee CG, Homer RJ, Zhu Z, et al. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med, 194:809-21.
113. Leeman M, Lejeune P, Melot C, et al. 1987. Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest, 91:662-6.
114. Lenhard JM, Kassel DB, Rocque WJ, et al. 1996. Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase. Biochem J, 316:751-8.
115. Lew DB, Nebigil C, Malik KU. 1992. Dual regulation by cAMP of beta-hexosaminidase-induced mitogenesis in bovine tracheal myocytes. Am J Respir Cell Mol Biol, 7:614-9.
116. Li L, Yee C, Beavo JA. 1999. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science, 283:848-51.
117. Lin CS, Lau A, Tu R, et al. 2000. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun, 268:628-35.
118. Lincoln TM, Hall CL, Park CR, et al. 1976. Guanosine 3′,5′-cyclic monophosphate binding proteins in rat tissues. Proc Natl Acad Sci U S A, 73:2559-63.
119. Lipworth BJ. 2005. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, 365:167-75.
120. Loher F, Schmall K, Freytag P, et al. 2003. The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther, 305:549-56.
121. Losco PE, Evans EW, Barat SA, et al. 2004. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol, 32:295-308.
122. Loughney K, Hill TR, Florio VA, et al. 1998. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene, 216:139-47.
123. Macdonald E, Van Der Lee H, Pocock D, et al. 2007. A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia. Neurorehabil Neural Repair, 21:486-96.
124. Mackenzie SJ, Baillie GS, McPhee I, et al. 2000. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem, 275:16609-17.
125. Mackenzie SJ, Baillie GS, McPhee I, et al. 2002. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol, 136:421-33.
126. Mackintosh C. 2004. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem J, 381:329-42.
127. Manning CD, Burman M, Christensen SB, et al. 1999. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol, 128:1393-8.
128. McAllister-Lucas LM, Haik TL, Colbran JL, et al. 1995. An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. J Biol Chem, 270:30671-9.
129. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, et al. 1993. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem, 268:22863-73.
130. McConnachie G, Langeberg LK, Scott JD. 2006. AKAP signaling complexes: getting to the heart of the matter. Trends Mol Med, 12:317-23.
131. McLaughlin MM, Cieslinski LB, Burman M, et al. 1993. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J Biol Chem, 268:6470-6.
132. Michaeli T, Bloom TJ, Martins T, et al. 1993. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem, 268, 12925-32.
133. 2+/ calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization. Biochim Biophys Acta, 1517:278-87.
134. Miki T, Taira M, Hockman S, et al. 1996. Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family. Genomics, 36:476-85.
135. Milatovich A, Bolger G, Michaeli T, et al. 1994. Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse. Somat Cell Mol Genet, 2075-86.
136. Mongillo M, McSorley T, Evellin S, et al. 2004. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res, 95:67-75.
137. Moore AR, Willoughby DA. 1995. The role of cAMP regulation in controlling inflammation. Clin Exp Immunol, 101:387-9.
138. Muller T, Engels P, Fozard JR. 1996. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sci, 17:294-8.
139. Mullershausen F, Russwurm M, Thompson WJ, Liu, et al. 2001. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol, 155:271-8.
140. Murthy KS. 2001. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J, 360:199-208.
141. Myou S, Fujimura M, Kamio Y, et al. 1999. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med, 160:817-20.
142. National Institute for Clinical Excellence (Nice). 2004. Chronic obstructive pulmonary disease. National clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59(Suppl 1):1-232.
143. Nemoz, G., Zhang, R., Sette, C. and Conti, M. (1996) Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett, 384, 97-102.
144. Newman, S. P., Rivero, X., Luria, X., Hooper, G. and Pitcairn, G. R. (1997) A scintigraphic study to evaluate the deposition patterns of a novel anti-asthma drug inhaled from the Cyclohaler dry powder inhaler. Adv Drug Deliv Rev, 26, 59-67.
145. Nielson CP, Vestal RE, Sturm RJ. 1990. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol, 86:801-8.
146. Novack JP, Charbonneau H, Bentley JK, et al. 1991. Sequence comparison of the 63-, 61-, and 59-kDa calmodulin-dependent cyclic nucleotide phosphodiesterases. Biochemistry, 30:7940-7.
147. O'connell JC, Mccallum JF, McPhee I, et al. 1996. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem J, 318: 255-61.
148. O'Shaughnessy TC, Ansari TW, Barnes NC. 1997. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med, 155:852-7.
149. Okada D, Asakawa S. 2002. Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP. Biochemistry, 41:9672-9.
150. Ouagued M, Martin-Chouly CA, Brinchault G, et al. 2005. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients. Pulm Pharmacol Ther, 18:49-54.
151. Pastan IH, Johnson GS, Anderson WB. 1975. Role of cyclic nucleotides in growth control. Annu Rev Biochem, 44:491-522.
152. Pauvert O, Salvail D, Rousseau E, et al. 2002. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol, 63:1763-72.
153. Peachell PT, Undem BJ, Schleimer RP, et al. 1992. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol, 148:2503-10.
154. Pooley L, Shakur Y, Rena G, et al. 1997. Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. Biochem J, 321:177-85.
155. Pozuelo Rubio M, Campbell DG, Morrice NA, et al. 2005. Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem J, 392:163-72.
156. Pozuelo Rubio M, Geraghty KM, Wong BH, et al. 2004. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J, 379:395-408.
157. Profita M, Chiappara G, Mirabella F, et al. 2003. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax, 58:573-9.
158. Rabe KF, Bateman ED, O'Donnell D, et al. 2005. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 366:563-71.
159. Rabe KF, Tenor H, Dent G, et al. 1993. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol, 264:L458-64.
160. Rascon A, Degerman E, Taira M, et al. 1994. Identification of the phosphorylation site in vitro for cAMP-dependent protein kinase on the rat adipocyte cGMP-inhibited cAMP phosphodiesterase. J Biol Chem, 269:11962-6.
161. Reinhardt RR, Chin E, Zhou J, et al. 1995. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest, 95:1528-38.
162. Rennard SI, Schachter N, Strek M, et al. 2006. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest, 129:56-66.
163. Richter W, Conti M. 2004. The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J Biol Chem, 279:30338-48.
164. Richter W, Day P, Agrawal R, et al. 2008. Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. Embo J, 27:384-93.
165. Robichaud A, Stamatiou PB, Jin SL, et al. 2002. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest, 110:1045-52.
166. Robicsek SA, Blanchard DK, Djeu JY, et al. 1991. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol, 42:869-77.
167. Rondinone CM, Carvalho E, Rahn T, et al. 2000. Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor. J Biol Chem, 275:10093-8.
168. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, et al. 1997. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest, 100:2611-21.
169. Rybalkin SD, Rybalkina I, Beavo JA, et al. 2002a. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res, 90:151-7.
170. Rybalkin SD, Rybalkina IG, Feil R, et al. 2002b. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem, 277:3310-7.
171. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, et al. 2003. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. Embo J, 22:469-78.
172. Saetta M, Baraldo S, Corbino L, et al. 1999. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 160:711-7.
173. Saetta M, Di Stefano A, Maestrelli P, et al. 1994. Airway eosinophilia in chronic bronchitis during exacerbations Am J Respir Crit Care Med, 150:1646-52.
174. Saetta M, Turato G, Maestrelli P, et al. 2001. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:1304-9.
175. Sasaki T, Kotera J, Yuasa K, et al. 2000. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun, 271:575-83.
176. Sastry BK, Narasimhan C, Reddy NK, et al. 2004. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol, 43:1149-53.
177. Schillace RV, Andrews SF, Liberty GA, et al. 2002. Identification and characterization of myeloid translocation gene 16b as a novel a kinase anchoring protein in T lymphocytes. J Immunol, 1681590-9.
178. Schlossmann J, Ammendola A, Ashman K, et al. 2000. Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature, 404:197-201.
179. Schlossmann J, Feil R, Hofmann F. 2003. Signaling through NO and cGMP-dependent protein kinases. Ann Med, 35:21-7.
180. Schudt C, Tenor H, Hatzelmann A. 1995. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J, 8:1179-83.
181. Sebkhi A, Strange JW, Phillips SC, et al. 2003. Phosphodiesterase types 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation, 107:3230-5.
182. Seldon PM, Barnes PJ, Meja K, et al. 1995. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol, 48:747-57.
183. Sette C, Conti M. 1996. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem, 271:16526-34.
184. Shakur Y, Pryde JG, Houslay MD. 1993. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem J, 292:677-86.
185. Shakur Y, Wilson M, Pooley L, et al. 1995. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem J, 306:801-9.
186. Sharma RK. 1991. Phosphorylation and characterization of bovine heart calmodulin-dependent phosphodiesterase. Biochemistry, 30:5963-8.
187. Sharma RK, Das SB, Lakshmikuttyamma A, et al. 2006. Regulation of calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1): review. Int J Mol Med, 18:95-105.
188. Sharma RK, Kalra J. 1993. Ginsenosides are potent and selective inhibitors of some calmodulin-dependent phosphodiesterase isozymes. Biochemistry, 32:4975-8.
189. Sharma RK, Seitz DP, Singh B. 2002. Localization and regulation of bovine eye calmodulin-dependent cyclic nucleotide phosphodiesterase by cyclic AMP-dependent protein kinase. Int J Mol Med, 10:17-23.
190. Sharma RK, Wang JH. 1985. Differential regulation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase. Proc Natl Acad Sci U S A, 82:2603-7.
191. Sharma RK, Wang JH. 1986. Calmodulin and Ca2+ -dependent phosphorylation and dephosphorylation of 63-kDa subunit-containing bovine brain calmodulin-stimulated cyclic nucleotide phosphodiesterase isozyme. J Biol Chem, 261:1322-8.
192. Sharma RK, Wang JH, Wu Z. 1997. Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem, 69:845-50.
193. Shepherd MC, Baillie GS, Stirling DI, et al. 2004. Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol, 142:339-51.
194. Smith CJ, Krall J, Manganiello VC, et al. 1993. Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun, 190:516-21.
195. Smith SJ, Brookes-Fazakerley S, Donnelly LE, et al. 2003. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol, 284:L279-89.
196. Smith SJ, Cieslinski LB, Newton R, et al. 2004. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido) -4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol, 66:1679-89.
197. Soderling SH, Beavo JA. 2000. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol, 12:174-9.
198. Sonnenburg WK, Seger D, Kwak KS, et al. 1995. Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases. J Biol Chem, 270:30989-1000.
199. Sturton G, Fitzgerald M. 2002. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest, 121:192S-6S.
200. Sung BJ, Hwang KY, Jean YH, et al. 2003. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature, 425:98-102.
201. Surks HK, Mochizuki N, Kasai Y, et al. 1999. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Ialpha. Science, 286:1583-7.
202. Sutherland EW. 1970. On the biological role of cyclic AMP. JAMA, 214:1281-8.
203. Szpirer C, Szpirer J, Riviere M, et al. 1995. Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP-specific phosphodiesterases 3 and 4. Cytogenet Cell Genet, 69:11-4.
204. Tenor H, Staniciu L, Schudt C, et al. 1995. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin Exp Allergy, 25:616-24.
205. Teo TS, Wang JH. 1973. Mechanism of activation of a cyclic adenosine 3′,5′-monophosphate phosphodiesterase from bovine heart by calcium ions. Identification of the protein activator as a Ca2+ binding protein. J Biol Chem, 248:5950-5.
206. Thomas MK, Francis SH, Corbin JD. 1990a. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem, 265, 14964-70.
207. Thomas MK, Francis SH, Corbin JD. 1990b. Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem, 265, 14971-8.
208. Thompson WJ. 1991. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther, 51:13-33.
209. Thompson WJ, Appleman MM. 1971. Characterization of cyclic nucleotide phosphodiesterases of rat tissues. J Biol Chem, 246:3145-50.
210. Thompson WJ, Ashikaga T, Kelly JJ, et al. 2002. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol, 63:797-807.
211. Tomlinson PR, Wilson JW, Stewart, et al. 1995. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem Pharmacol, 49:1809-19.
212. Torphy TJ. 1998. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med, 157:351-70.
213. Torphy TJ, Barnette MS, Underwood DC, et al;. 1999. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther, 12:131-5.
214. Torphy TJ, Undem BJ, Cieslinski LB, et al. 1993. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther, 265:1213-23.
215. Toward TJ, Smith N, Broadley KJ. 2004. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med, 169:227-34.
216. Tsoumakidou M, Demedts IK, Brussel]e GG, et al. 2008. Dendritic cells in COPD: new players in an old game. Am J Respir Crit Care Med, In press.
217. Ukita T, Sugahara M, Terakawa Y, et al. 1999. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives. J Med Chem, 42:1088-99.
218. Verde I, Pahlke G, Salanova M, et al. 2001. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem, 276:11189-98.
219. Wouters EF. 2002. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax, 57:1067-70.
220. Wright KF, Turner CR, Jayasinghe-Beck R, et al. 1997. Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor. Can J Physiol Pharmacol, 75:1001-8.
221. Wyatt TA, Naftilan AJ, Francis SH, et al. 1998. ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol, 274:H448-55.
222. Xu RX, Hassell AM, Vanderwall D, et al. 2000. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science, 288:1822-5.
223. Yan C, Zhao AZ, Bentley JK, et al. 1996. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem, 271:25699-706.
224. Yanaka N, Kotera J, Ohtsuka A, et al. 1998. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem, 255:391-9.
225. Yang G, Mcintyre KW, Townsend RM, et al. 2003. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol, 171:6414-20.
226. Zhang KY, Card GL, Suzuki Y, et al. 2004. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell, 15:279-86.
227. Zhao L, Mason NA, Morrell NW, et al. 2001. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation, 104:424-8.
228. Zhou G, Bao ZQ, Dixon JE. 1995. Components of a new human protein kinase signal transduction pathway. J Biol Chem, 270:12665-9.